Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary
Notice bibliographique
Résumé
Plain Language SummaryWhat is this summary about?This summary explains the results of a study looking at the long-term effects of a treatment called evinacumab. This study included people aged over 12 years with homozygous familial hypercholesterolemia, also known as HoFH. HoFH is a rare genetic disorder that makes the liver less able to remove excess ‘bad’ cholesterol (called low-density lipoprotein cholesterol, or LDL-C) from the body. LDL-C is considered ‘bad’ cholesterol because it increases the risk of heart disease and stroke. High levels of LDL-C increase the risk of developing serious heart problems early in life. Treatment options for lowering LDL-C often do not work very well for people with HoFH. Evinacumab is a medicine that is approved for the treatment of HoFH as an add-on to other therapies that lower LDL-C. The effect of evinacumab on heart problems such as heart attacks, stroke, or death is not known. In the UK, evinacumab is approved for people with HoFH aged 6 months and above. In Canada and the USA, evinacumab is approved for people with HoFH aged 5 years and above. In the European Union/European Economic Area, evinacumab is approved for people with HoFH aged 6 months and above. In Japan, evinacumab is approved for all ages of people with HoFH. More recently, evinacumab has also been approved in Brazil and Israel.What were the results?People with HoFH who took part in the study were treated with evinacumab every 4 weeks for up to 44 months.After 6 months of treatment, LDL-C levels were almost 44% lower than when people started the study.Treatment-emergent adverse events, also called TEAEs, were reported by 80% of people in the study but most of these were mild (23.3%) or moderate (41.4%) in severity. The most commonly reported side effects which happened during the study were common cold, COVID-19, headache, flu-like illness, general pain, back pain, nausea, and cough. The study researchers determined that most of these reported side effects (91%) were not related to the use of evinacumab.No serious TEAEs were considered related to evinacumab treatment. Nearly all of the people (97%) could continue with the study treatment and, based on this, the researchers concluded that evinacumab was generally well tolerated.What do the results mean?This study showed that evinacumab lowered ‘bad’ cholesterol in people with HoFH, and that this result lasted for a long period of time.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».